» Articles » PMID: 32944397

Serum MiR-339-3p As a Potential Diagnostic Marker for Non-small Cell Lung Cancer

Overview
Journal Cancer Biol Med
Specialty Oncology
Date 2020 Sep 18
PMID 32944397
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

: MicroRNA (miRNA), a short noncoding RNA, is claimed to be a potential blood-based biomarker. We aimed to identify and evaluate miRNAs as diagnostic biomarkers for non-small cell lung cancer (NSCLC). : Profiles of 745 miRNAs were screened in the serum of 8 patients with NSCLC and 8 age- and sex-matched controls using TaqMan low-density arrays (TLDAs) and validated in 25 patients with NSCLC and 30 with other lung diseases (OLs) as well as in 19 healthy persons (HPs). The diagnostic performance of the candidate miRNAs was assessed in 117 cases of NSCLC and 113 OLs using quantitative real-time polymerase chain reaction (qRT-PCR). Differences in miRNA expression between patients with NSCLC and controls were assessed using the Mann-Whitney U test. The area under receiver operating characteristic (ROC) curve (AUC) was obtained based on the logistic regression model. : Ten miRNAs were found to be differentially expressed between patients with NSCLC and controls, including miR-769, miR-339-3p, miR-339-5p, miR-519a, miR-1238, miR-99a#, miR-134, miR-604, miR-539, and miR-342. The expression of miR-339-3p was significantly higher in patients with NSCLC than in those with OLs ( < 0.001) and HPs ( = 0.020). ROC analysis revealed an miR-339-3p expression AUC of 0.616 [95% confidence interval (CI): 0.561-0.702]. The diagnostic prediction was increased (AUC = 0.706, 95% CI: 0.649-0.779) in the model combining miR-339-3p expression and other known risk factors (i.e., age, smoking status, and drinking status). : MiR-339-3p was significantly upregulated in patients with NSCLC compared with participants without cancer, suggesting a diagnostic prediction value for high-risk individuals. Therefore, miR-339-3p expression could be a potential blood-based biomarker for NSCLC.

Citing Articles

Biomarkers Suitable for Early Detection of Intrathoracic Cancers in Primary Care: A Systematic Review.

Hamad W, Grigore B, Walford H, Peters J, Alexandris P, Bonfield S Cancer Epidemiol Biomarkers Prev. 2024; 34(1):19-34.

PMID: 39400573 PMC: 11712036. DOI: 10.1158/1055-9965.EPI-24-0713.


Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study.

Petracci E, Pasini L, Urbini M, Felip E, Stella F, Davoli F J Exp Clin Cancer Res. 2024; 43(1):241.

PMID: 39169404 PMC: 11340091. DOI: 10.1186/s13046-024-03156-y.


hsa_circ_0020378 regulating miR-339-3p/COL1A1 promotes osteosarcoma progression.

Liu L, Huang W Cancer Biol Ther. 2023; 24(1):2274120.

PMID: 37978903 PMC: 10761020. DOI: 10.1080/15384047.2023.2274120.


Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.

Garbo E, Del Rio B, Ferrari G, Cani M, Napoli V, Bertaglia V Cancers (Basel). 2023; 15(19).

PMID: 37835468 PMC: 10571819. DOI: 10.3390/cancers15194774.


Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications.

Liu Y, Ding W, Wang J, Ao X, Xue J Front Oncol. 2023; 13:1256537.

PMID: 37746261 PMC: 10514911. DOI: 10.3389/fonc.2023.1256537.


References
1.
Niu Y, Su M, Wu Y, Fu L, Kang K, Li Q . Circulating Plasma miRNAs as Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling. Cancer Epidemiol Biomarkers Prev. 2018; 28(2):327-336. DOI: 10.1158/1055-9965.EPI-18-0723. View

2.
Medina-Villaamil V, Martinez-Breijo S, Portela-Pereira P, Quindos-Varela M, Santamarina-Cainzos I, Anton-Aparicio L . Circulating MicroRNAs in blood of patients with prostate cancer. Actas Urol Esp. 2014; 38(10):633-9. DOI: 10.1016/j.acuro.2014.02.008. View

3.
Switlik W, Karbownik M, Suwalski M, Kozak J, Szemraj J . Serum miR-210-3p as a Potential Noninvasive Biomarker of Lung Adenocarcinoma: A Preliminary Study. Genet Test Mol Biomarkers. 2019; 23(5):353-358. DOI: 10.1089/gtmb.2018.0275. View

4.
Halvorsen A, Bjaanaes M, LeBlanc M, Holm A, Bolstad N, Rubio L . A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget. 2016; 7(24):37250-37259. PMC: 5095073. DOI: 10.18632/oncotarget.9363. View

5.
Wang H, Peng R, Wang J, Qin Z, Xue L . Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018; 10:59. PMC: 5913875. DOI: 10.1186/s13148-018-0492-1. View